OOIR: Observatory of International Research

Papers

(The TQCC of Pituitary is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Development of a cost-effective diagnostic algorithm incorporating transcription factor immunohistochemistry in the evaluation of pituitary tumours	160
Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency	52
Prevalence and risk factors of colon polyps and other colonic lesions in acromegaly: Insights from colonoscopy screening	52
Patient perceptions of pituitary incidentaloma diagnosis and follow-up: a Pituitary Society international patient survey	42
Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas	40
The impact of facility type and volume on treatment and overall survival in craniopharyngioma	38
Substance P and Neurokinin-1 receptor are overexpressed in adamantinomatous craniopharyngioma than in the pituitary gland	37
Predictors of biochemical remission after transsphenoidal surgery in a large cohort of acromegaly patients	34
Clinicopathological features and outcomes of immature PIT-1 lineage tumors: A high-risk pituitary neuroendocrine tumor/pituitary adenoma subtype per WHO 2022	32
Correction to: Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies	29
Idiopathic central diabetes insipidus in a large cohort of patients: the hypopituitarism ENEA rare observational (HEROS) study	28
Semaglutide treatment in hypothalamic obesity: Two-Year outcomes on body composition, appetite, and quality of life	26
Pituitary: hic manebimus optime	26
The assessment of thiol-disulfide homeostasis and ıschemia-modified albumin levels in patients with acromegaly	24
Gigantism: microsurgical treatment by transsphenoidal approach and prognostic factors	24
Genetic models of Cushing’s disease	23
Pituitary metastases: a case series and scoping review	20
The efficacy of minimally invasive intraoperative ultrasound in endoscopic pituitary surgery	20
Acromegaly increases depressive symptoms and reduces quality of life of cohabitants	20
Sleep disruption in patients with active and treated endogenous Cushing’s syndrome	19
Basal cortisol in relation to metyrapone confirmation in predicting adrenal insufficiency after pituitary surgery	18
Non-written guidelines in pituitary tumor surgery. The hidden curriculum	18
ACRODAT and SAGIT for the assessment of disease activity in acromegaly: a multicenter study of the Veneto region in Italy	18
Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study	18
Psychological profiles of patients with acromegaly: personality traits, quality of life, and clinical correlates	18

Hospital frailty risk score predicts postoperative outcomes after endoscopic endonasal resection of non-functioning pituitary adenomas	18
Evaluating pituitary tumor management: aligning with pituitary tumor centers of excellence criteria	17
Consensus on acromegaly complications: an update	17
Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience	17
Diagnosis of growth hormone deficiency: searching for Consensus along life	16
Correction: Development and validation of a novel treatment adherence, satisfaction and knowledge questionnaire (TASK-Q) for adult patients with hypothalamic-pituitary disorders	16
Hypopituitarism and bone disease: pathophysiology, diagnosis and treatment outcomes	16
Complications and mortality of Cushing’s disease: report on data collected over a 20-year period at a referral centre	16
IGF-1 is positively associated with BMI in patients with acromegaly	15
Predicting tumor consistency and extent of resection in non-functioning pituitary tumors	15
A post-hoc internal validation of arginine-stimulated copeptin cut-offs for diagnosing AVP deficiency (central diabetes insipidus)	15
The diagnosis and prevalence of hypoprolactinemia in patients with panhypopituitarism and the effects on depression and sexual functions	15
Pituitary surgery in Cushing’s disease: first line treatment and role of reoperation	15
Diagnostic performance of desmopressin stimulation test in pediatric cushing’s disease	15
Psychiatric morbidity in acromegaly: a cohort study and meta-analysis of the literature	14
TSH-secreting pituitary adenomas and bone	14
Shared decision-making and detection of comorbidities in an online acromegaly consultation with and without the Acromegaly Disease Activity Tool ACRODAT® using the simulated person approach	14
Commentary: The updated European society of endocrinology clinical practice guideline for the management of aggressive pituitary tumors and pituitary carcinomas	14
Medical management pathways for Cushing’s disease in pituitary tumors centers of excellence (PTCOEs)	14
Cushing’s disease and bone	14
Clinical presentation, predictive factors and management of patients with Nelson syndrome: a retrospective study	13
Reappraising prediction of surgical complexity of non-functioning pituitary adenomas after transsphenoidal surgery: the modified TRANSSPHER grade	13
From misclassified AIP variant to carney complex: a case report and retrospective evaluation of PRKAR1A in pituitary tumor predisposition	13
Outcomes in surgical management of microprolactinomas: an international multi-institutional series	13
Response to letter to the editor “Hypopituitarism and COVID-19, what else?”	13
Circadian rhythm proteins as potential biomarkers in pituitary adenomas: an immunohistochemical analysis	13
Development and validation of clinical screening systems for Cushing disease in the United States	13
Generating novel pituitary datasets from open-source imaging data and deep volumetric segmentation	13
Copeptin after pituitary surgery: is it worth measuring?	12
Clinical, surgical, and endocrine outcome following treatment of posterior pituitary tumors: a retrospective cohort study	12
Pituitary surgery and COVID	12
The impact of growth hormone (GH) on immunosenescence: exploring the role of B and T cells	12
Cabergoline treatment for surgery-naïve non-functioning pituitary macroadenomas	12
Muscle dysfunction is associated with poor quality of life in long-term controlled patients with acromegaly	12
Validation and modification of the PANOMEN 3 classification for predicting long-term recurrence/progression and quality of life in patients with pituitary adenomas: a multicentre retrospective cohort	11
Is diabetes with acromegaly for life?	11
[68 Ga]-DOTATATE PET/MR-based evaluation of physiologic somatostatin receptor 2 expression in the adult pituitary gland as a function of age and sex in a prospective cohort	11
The clinicopathological PANOMEN-3 classification predicts pituitary adenoma prognosis: a real-world retrospective single center study of a surgically treated cohort	11
Anemia in acromegaly: Prevalence, etiologies, and predictors from a large tertiary center cohort	11
Prevalence and evolution of hypertension in a large Iberian cohort of patients with acromegaly	11
Mortality in patients with dopamine agonist-treated hyperprolactinemia: a large matched-cohort study	11
Clinical and prognostic implications of pituitary macroadenomas (PitNets) grading: a monocentric experience	11
Long COVID and pituitary dysfunctions: a bidirectional relationship?	10
SAGIT®, ACRODAT®, PANOMEN 3… time to implement tools for management of acromegaly..?	10
Determinants of remission and recurrence following transsphenoidal surgery for prolactinoma: a single-center experience	10
Serum IGF-1 May be less reliable when assessing the GH-IGF-1 axis in the elderly	10
Serum biomarkers of colonic polyps in patients with acromegaly: a meta-analysis and systematic review	10
Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis	9
Demonstration of the inferior intercavernous sinus is closely linked to the extent of pneumatization of the sphenoid sinus: useful information for the pituitary surgeon	9
Impulse control disorders and their relationship with psychopathology in patients treated with cabergoline for hyperprolactinaemia	9

Nelson’s syndrome: reappraisal of an uncommon disease	9
Determinants of skeletal fragility in acromegaly: a systematic review and meta-analysis	9
Headache in patients with non-functioning pituitary adenoma before and after transsphenoidal surgery – a prospective study	9
Surgical treatment of cystic pituitary adenomas: literature-based definitions and postoperative outcomes	9
The effect of glucose dynamics on plasma copeptin levels upon glucagon, arginine, and macimorelin stimulation in healthy adults	9
Usefulness of a clinicopathological classification in predicting treatment-related outcomes and multimodal therapeutic approaches in pituitary adenoma patients: retrospective analysis on a Portuguese	9
Clinical and prognostic significance of granulation patterns in somatotroph adenomas/tumors of the pituitary: a meta-analysis	9
Measuring pituitary tumor volume: a comparison of the simplified and non-simplified ellipsoid equation with the 3D planimetric volume assessment	9
Refractory nonfunctioning pituitary adenomas	9
Growth hormone insensitivity and adipose tissue: tissue morphology and transcriptome analyses in pigs and humans	8
A Retrospective cohort study of Knosp grade reporting of cavernous sinus invasion in pituitary macroadenomas	8
Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma	8
Diffusion-weighted imaging does not seem to be a predictor of consistency in pituitary adenomas	8
Proportion and predictors of Hypogonadism Recovery in Men with Macroprolactinomas treated with dopamine agonists	8
Importance of 24 h ambulatory blood pressure monitoring in patients with acromegaly and correlation with cardiac magnetic resonance findings	8
Changes in pituitary adenoma patient presentation and outcomes during the COVID pandemic at a Pituitary Center of Excellence	8
Outcomes of stereotactic radiosurgery in nelson’s syndrome: a systematic review and Meta-Analysis	8
Skeletal fragility in pituitary disease: how can we predict fracture risk?	8
Genetic evaluation of pediatric pituitary adenomas and USP8-related genotype-phenotype correlations in Cushing’s disease	8
Alert: misinformation that may hurt patients with both adrenal insufficiency and AVP deficiency	8
Pituitary stalk biopsy – A systematic review of the safety and efficacy of stalk lesion biopsy	7
Cushing’s disease: role of preoperative and primary medical therapy	7
Can we predict the risk of venous thromboembolism in patients with Cushing’s syndrome: a nationwide cohort analysis	7
Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysis	7
High prevalence of morphometric vertebral fractures opportunistically detected on thoracic radiograms in patients with non-functioning pituitary adenoma	7
Giant prolactinomas, a detailed analysis of 196 adult cases	7
The somatotroph pituitary gland function in high-aged multimorbid hospitalized patients with IGF-I deficiency	7
TGFBR3L is associated with gonadotropin production in non-functioning gonadotroph pituitary neuroendocrine tumours	7
Correction: consensus on criteria for acromegaly diagnosis and remission	7
Cushing’s syndrome: Guidance on thromboprophylaxis at last	7
Posterior hypothalamic involvement on pre-operative MRI predicts hypothalamic obesity in craniopharyngiomas	7
An update on, and genetics of refractory adenomas of childhood	7
The diagnosis of GH deficiency in adult β-thalassemic patients: are two different stimulation tests necessary to improve specificity?	7
Surgical management in very elderly patients with pituitary adenoma: a multivariable assessment of the surveillance, epidemiology, and end results database	7
Recent progress in the understanding of psychological complications of acromegaly: toward a longitudinal clinical phenotype	7
HLA analysis of immune checkpoint inhibitor-induced and idiopathic isolated ACTH deficiency	7
The effect of growth hormone replacement therapy on craniopharyngioma recurrence: a systematic review and meta-analysis	7
Postoperative weight gain following endoscopic endonasal surgery for craniopharyngiomas in children and adults: A retrospective cohort study	6
How to manage intolerance to dopamine agonist in patients with prolactinoma	6
Pregnancy and delivery after surgical remission in women with prolactinomas desiring pregnancy: Refining surgical indications	6
Selective resection of the medial wall of the cavernous sinus in pituitary surgery: results of a prospective single center analysis	6
Pituitary acting drugs: cabergoline and pasireotide	6
Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre	6
Idiopathic isolated adrenocorticotropic hormone deficiency: a systematic review of a heterogeneous and underreported disease	6
Clinical use of [18F]fluoro-ethyl-L-tyrosine PET co-registered with MRI for localizing prolactinoma remnants	6
Critical views for safe surgical phase progression in endoscopic endonasal transsphenoidal pituitary adenoma resection: modified Delphi consensus	6
Prolactinoma-associated headache: Clinical and radiological correlates and long-term outcomes	6
Correction: Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study	6
Reported baseline variables in transsphenoidal surgery for pituitary adenoma over a 30 year period: a systematic review	6
Old and new pituitary biomarkers: evidence for sex-specificity	6
Sex differences in the clinical presentation, management and long-term outcomes of pituitary tumors in children and adolescents	6
The comprehensive evaluation of oral and fecal microbiota in patients with acromegaly	6
Syndrome of inappropriate antidiuresis/hyponatremia in COVID-19	6
Sellar and perisellar meningiomas: effects on pituitary function in a Spanish cohort observational study	6
Pituitary Tumor Centers of Excellence (PTCOE) should now include neuro-oncologic input	6
Patients with langerhans cell histiocytosis and hypothalamic-pituitary involvement: insights from the HEROS study cohort	6
Long-term metabolic effectiveness and safety of growth hormone replacement therapy in patients with adult growth hormone deficiency: a single-institution study in Japan	6